Cardiology Referrals for High Cardiovascular Risk Patients in a Rural New Zealand General Practice Community

2021 ◽  
Vol 30 ◽  
pp. S69
Author(s):  
L. Gilheany-Black ◽  
M. Davis
Keyword(s):  
General Practice ◽  
Cardiovascular Risk ◽  
New Zealand ◽  
High Cardiovascular Risk ◽  
Risk Patients ◽  
Practice Community

scholarly journals Why are there gaps in our management of those with high cardiovascular risk?

2012 ◽  
Vol 4 (1) ◽  
pp. 21 ◽  
Author(s):  
Fiona Doolan-Noble ◽  
Jocelyn Tracey ◽  
Stewart Mann
Keyword(s):  
Health Care ◽  
General Practice ◽  
Primary Health Care ◽  
Cardiovascular Risk ◽  
New Zealand ◽  
Barriers And Facilitators ◽  
Care Providers ◽  
High Cardiovascular Risk ◽  
Text Data ◽  
Primary Health

INTRODUCTION: Multiple New Zealand and other international studies have identified gaps in the management of those identified at high risk of a future cardiovascular (CV) event. This study sought to explore the views of health professionals about the barriers and facilitators present within the current primary health care system to the optimal management of those at high CV risk. METHODS: This qualitative study utilised a focus group methodology to examine the barriers and facilitators within primary health care (PHC), and employed a general inductive approach to analyse the text data. FINDINGS: The analysis of text data resulted in the emergence of interrelated themes, underpinned by subthemes. The patient, their circumstances and their characteristics and perceptions provided the first key theme and subthemes. The next key theme was primary health care providers, with subthemes of communication and values and beliefs. The general practice was the third theme and included multiple subthemes: implementation planning and pathway development, time and workload and roles and responsibilities. The final main theme was the health system with the subthemes linking to funding and leadership. CONCLUSION: This study determined the factors that act as barriers and facilitators to the effective management of those at high CV risk within the New Zealand PHC sector. General practice has a pivotal role in preventive health care, but to succeed there needs to be a refocusing of the PHC sector, requiring support from policy makers, District Health Boards and Primary Health Organisations, as well as those working in the sector. KEYWORDS: Primary health care; high cardiovascular risk management; general practitioners; practice nurses; barriers; facilitators

scholarly journals Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice

2018 ◽  
Vol 271 ◽  
pp. 120-127 ◽  
Author(s):  
Marcello Arca ◽  
David Ansell ◽  
Maurizio Averna ◽  
Francesca Fanelli ◽  
Katherine Gorcyca ◽  
...  
Keyword(s):  
General Practice ◽  
Cardiovascular Risk ◽  
Goal Attainment ◽  
High Cardiovascular Risk ◽  
Risk Patients ◽  
Very High

The effect of PCSK9 Inhibitor EVOLOCUMAB on aldosterone among high cardiovascular risk patients

2020 ◽  
Author(s):  
Elena Lzkhakov ◽  
Yakov Shacham ◽  
Mariana Yaron ◽  
Merav Serebro ◽  
Karen Tordjman ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Cardiovascular Risk ◽  
Pcsk9 Inhibitor ◽  
Risk Patients

Telmisartan in High Cardiovascular Risk Patients

2012 ◽  
Vol 8 (1) ◽  
pp. 10 ◽  
Author(s):  
Roland Asmar ◽  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Ace Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
High Cardiovascular Risk ◽  
Raas Blockade ◽  
Risk Patients ◽  
Receptor Blockers ◽  
Current Guidelines

The worldwide morbidity and mortality burden of cardiovascular disease (CVD) is overwhelming and caused by increasing life expectancy and an epidemic of risk factors, including hypertension. Therapeutic options targeting different areas of the renin–angiotensin–aldosterone system (RAAS) to disrupt pathophysiological processes along the cardiovascular continuum are available. Angiotensin-converting enzyme (ACE) inhibitors are first-line treatments for CVD and angiotensin receptor blockers (ARBs) are suitable alternatives. Both ACE inhibitors and ARBs prevent CVD by lowering blood pressure (BP). Additionally, several studies have demonstrated that RAAS blockade can reduce cardiovascular risk beyond what might be expected from BP lowering alone. However, the ARBs are not all equally effective. Telmisartan is a long-lasting ARB that effectively controls BP over the full 24-hour period. Recently, the Ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET) study showed that telmisartan reduces cardiovascular events in high cardiovascular risk patients similarly to the gold standard ACE inhibitor ramipril beyond BP lowering alone, but with a better tolerability. Based on the results of the ONTARGET and Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) studies, telmisartan is indicated for the reduction of cardiovascular morbidity. This article aims to review current guidelines for the management of CVD and consider key data from clinical trials and clinical practice evaluating the role of telmisartan in CVD.

Use of Left Ventricular Strain to Predict Heart Failure and Mortality in High Cardiovascular Risk Patients

2018 ◽  
Vol 27 ◽  
pp. S285-S286
Author(s):  
K. Haji ◽  
T. Marwick ◽  
C. Neil ◽  
S. Stewart ◽  
M. Carington ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Risk ◽  
Left Ventricular ◽  
High Cardiovascular Risk ◽  
Left Ventricular Strain ◽  
Risk Patients

Real-World Characteristics And Risk Of Cardiovascular Events In High Cardiovascular Risk Patients In France

2019 ◽  
Vol 287 ◽  
pp. e180
Author(s):  
G. Désaméricq ◽  
F. Fagnani ◽  
C. Emery ◽  
J. Gourmelen ◽  
J.V. Chauny ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Real World ◽  
Cardiovascular Events ◽  
High Cardiovascular Risk ◽  
Risk Patients

scholarly journals Body mass index, cognitive deficit and depressive symptoms in high cardiovascular risk patients

2010 ◽  
Vol 4 (4) ◽  
pp. 313-319 ◽  
Author(s):  
Amanda Lucas da Costa ◽  
Juliana Santos Varela ◽  
Matheus Roriz Cruz ◽  
Andry Fitterman Costa ◽  
Paulo Dornelles Picon ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Depressive Symptoms ◽  
Cardiovascular Risk ◽  
Geriatric Depression Scale ◽  
Depression Scale ◽  
Obese Patients ◽  
High Cardiovascular Risk ◽  
Point Increase ◽  
Risk Patients ◽  
Relationship Of

Abstract To evaluate the relationship of obesity, cognitive impairment and depressive symptoms in patients with high cardiovascular risk. Methods: A sample of 93 patients aged 50 years or older was selected from the Center of Dyslipidemia and High Cardiovascular Risk from Hospital de Clínicas de Porto Alegre (HCPA). Patients with stroke were excluded. For cognitive evaluation, the MMSE (Mini Mental State Examination) was used. A score of 24 or less was considered as cognitive impairment, and for those who had 4 years or less of education, the cutoff point was 17. The GDS-15 (Geriatric Depression Scale) was also used, with the cutoff of 6 for presence of depressive symptoms. Results: Obese patients showed lower mean MMSE scores compared to non-obese patients (p=0.0012). Additionally, for every one point increase in BMI above 30 there was a 27% increase in the chances of the patient having cognitive impairment. The obese patients presented 31% chance of having cognitive impairment compared with overweight subjects. Conclusions: Our findings corroborated the association between obesity and cognitive impairment in high cardiovascular risk patients. This association however, was not observed for depressive symptoms.

Sign in / Sign up

Export Citation Format

Share Document